The ongoing Phase Ib/IIa trial (NCT04146051) involving Descartes-08 rCAR-T cells for the treatment of generalized MG entailed transfecting mRNA-encoding anti-BCMA (B-cell maturation antigen) into CD8+ T cells. The gene discussed is TNFRSF17; the disease is myasthenia gravis.